Soybean Futures Slip as Traders Await Trump-Xi Trade Signals 
China Consumer Stocks Near Decade Lows as AI Shares Surge 
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue 
Canadian Dollar Faces Pressure as Fed-BoC Policy Gap Widens 
Gold Prices Fall as Treasury Yields Rise on Fed Rate Hike Bets 
Fed Unveils Stablecoin Rules Under GENIUS Act 
UK PM Burnham to Unveil Economic Vision at Labour Conference 
Japanese Bank Stocks Surge as Bond Yields Fuel Rate Hike Bets 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
US Stock Futures Fall as Treasury Yields Surge Ahead of Trump-Xi Summit 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
Asian Stocks Fall as Surging Bond Yields Rattle Markets 
Japanese Yen Rebounds as Trump Flags Currency Weakness 
Gold Holds Near $4,275 as Rising Treasury Yields Fuel Fed Rate Hike Bets 
Trump to Ease U.S. Fuel-Economy Standards 
Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
Add as a preferred source on Google
Roche CEO Urges FTC to Block Novo Nordisk's Acquisition of Catalent
Roche's CEO, Thomas Schinecker, has called on authorities to prevent Novo Nordisk’s controlling shareholder, Novo Holdings, from acquiring contract drug manufacturer Catalent. Schinecker voiced concerns about the potential negative impact on competition, particularly for smaller industry players. "While this doesn’t directly affect us, it could restrict options for smaller competitors if the number of available contract manufacturers decreases," he stated during a media call following Roche's quarterly sales report.
Consumer advocacy groups and labor unions recently petitioned the U.S. Federal Trade Commission (FTC) to intervene against the acquisition, citing risks to competition in the market for weight loss drugs and advanced gene therapies. They argued that the deal could limit opportunities for rivals like Amgen, Pfizer, Roche, and AstraZeneca, all of whom are developing obesity treatments, some based on complex peptides.
Other companies, such as Viking Therapeutics, Structure Therapeutics, and Sun Pharma, could also be impacted by this acquisition.
In contrast, Novo Holdings has defended its position, asserting a "pro-competitive rationale" for the deal. Teresa Graham, head of Roche's pharmaceutical division, reassured stakeholders that Roche is well-prepared, stating, "We have secured capacity with other contract manufacturing organizations and are confident in our production capabilities."
Roche plans to utilize a combination of in-house and external manufacturing for its forthcoming obesity drug launches, ensuring a steady supply chain.
